Eurand’s NDA for Zentase was accepted and has been granted priority review by FDA. Gearoid Faherty, chief executive officer of Eurand, commented, “We are extremely pleased with the FDA decision to grant Zentase priority review. We understand that the typical FDA review period of a drug with priority review status is six months versus a standard 10-month review. In the interim, we remain focused on the build-out of our U.S. specialty sales force in preparation for the potential commer...